Search Results - "Guerra Alia, Eva M"

Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial by Sabatier, Renaud, Rousseau, Frédérique, Joly, Florence, Cropet, Claire, Montégut, Coline, Frindte, Johanna, Cinieri, Saverio, Guerra Alía, Eva M., Polterauer, Stephan, Yoshida, Hiroyuki, Vergote, Ignace, Colombo, Nicoletta, Hietanen, Sakari, Largillier, Rémi, Canzler, Ulrich, Gratet, Alain, Marmé, Frederik, Favier, Laure, Pujade-Lauraine, Eric, Ray-Coquard, Isabelle

“…The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in…”
Get full text

Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study by Rubio, María Jesús, Manzano, Aránzazu, de Sande, Luis Miguel, Estévez-García, Purificación, Gordon, María Del Mar, de Prado, Diego Soto, de Aranguiz, Blanca Hernando Fernández, Guerra-Alia, Eva M, Carbó-Bagué, Anna, Romero, Ignacio, Corbellas, Miguel, González-Haba, Alba, Robles-Barraza, Carlos E, Martínez-García, Jerónimo, González-Martín, Antonio

“…Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is approved for the treatment of patients with platinum-sensitive relapsed ovarian…”
Get full text

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775 by Makker, Vicky, Colombo, Nicoletta, Casado Herráez, Antonio, Monk, Bradley J, Mackay, Helen, Santin, Alessandro D, Miller, David S, Moore, Richard G, Baron-Hay, Sally, Ray-Coquard, Isabelle, Ushijima, Kimio, Yonemori, Kan, Kim, Yong Man, Guerra Alia, Eva M, Sanli, Ulus A, Bird, Steven, Orlowski, Robert, McKenzie, Jodi, Okpara, Chinyere, Barresi, Gianmaria, Lorusso, Domenica

“…JCO We report the final prespecified analysis for overall survival (OS), along with updated progression-free survival (PFS) and objective response rate (ORR),…”
Get full text

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial by González-Martín, Antonio, Desauw, Christophe, Heitz, Florian, Cropet, Claire, Gargiulo, Piera, Berger, Regina, Ochi, Hiroyuki, Vergote, Ignace, Colombo, Nicoletta, Mirza, Mansoor R., Tazi, Youssef, Canzler, Ulrich, Zamagni, Claudio, Guerra-Alia, Eva M., Levaché, Charles B., Marmé, Frederik, Bazan, Fernando, de Gregorio, Nikolaus, Dohollou, Nadine, Fasching, Peter A., Scambia, Giovanni, Rubio-Pérez, María J., Milenkova, Tsveta, Costan, Cristina, Pautier, Patricia, Ray-Coquard, Isabelle

“…Background: PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab…”
Get full text

Survival With Cemiplimab in Recurrent Cervical Cancer by Tewari, Krishnansu S., Monk, Bradley J., Vergote, Ignace, Miller, Austin, de Melo, Andreia C., Kim, Hee-Seung, Kim, Yong Man, Lisyanskaya, Alla, Samouëlian, Vanessa, Lorusso, Domenica, Damian, Fernanda, Chang, Chih-Long, Gotovkin, Evgeniy A., Takahashi, Shunji, Ramone, Daniella, Pikiel, Joanna, Maćkowiak-Matejczyk, Beata, Alía, Eva M. Guerra, Colombo, Nicoletta, Makarova, Yulia, Rischin, Danny, Lheureux, Stephanie, Hasegawa, Kosei, Fujiwara, Keiichi, Li, Jingjin, Jamil, Shaheda, Jankovic, Vladimir, Chen, Chieh-I, Seebach, Frank, Weinreich, David M., Yancopoulos, George D., Lowy, Israel, Mathias, Melissa, Fury, Matthew G., Oaknin, Ana

“…(Abstracted from N Engl J Med 2022;386(6):544–555) Despite widespread implementation of cervical cancer screening and prevention programs including cytologic…”
Get full text

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer by Ray-Coquard, Isabelle, Pautier, Patricia, Pignata, Sandro, Pérol, David, González-Martín, Antonio, Berger, Regina, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Mäenpää, Johanna, Selle, Frédéric, Sehouli, Jalid, Lorusso, Domenica, Guerra Alía, Eva M, Reinthaller, Alexander, Nagao, Shoji, Lefeuvre-Plesse, Claudia, Canzler, Ulrich, Scambia, Giovanni, Lortholary, Alain, Marmé, Frederik, Combe, Pierre, de Gregorio, Nikolaus, Rodrigues, Manuel, Buderath, Paul, Dubot, Coraline, Burges, Alexander, You, Benoît, Pujade-Lauraine, Eric, Harter, Philipp

“…When used as maintenance therapy, the PARP inhibitor olaparib provided a significant progression-free survival benefit in women with ovarian cancer who had a…”
Get full text

Survival with Cemiplimab in Recurrent Cervical Cancer by Tewari, Krishnansu S, Monk, Bradley J, Vergote, Ignace, Miller, Austin, de Melo, Andreia C, Kim, Hee-Seung, Kim, Yong Man, Lisyanskaya, Alla, Samouëlian, Vanessa, Lorusso, Domenica, Damian, Fernanda, Chang, Chih-Long, Gotovkin, Evgeniy A, Takahashi, Shunji, Ramone, Daniella, Pikiel, Joanna, Maćkowiak-Matejczyk, Beata, Guerra Alía, Eva M, Colombo, Nicoletta, Makarova, Yulia, Rischin, Danny, Lheureux, Stephanie, Hasegawa, Kosei, Fujiwara, Keiichi, Li, Jingjin, Jamil, Shaheda, Jankovic, Vladimir, Chen, Chieh-I, Seebach, Frank, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Mathias, Melissa, Fury, Matthew G, Oaknin, Ana

“…Cervical cancer that relapses after platinum-containing chemotherapy is often refractory to salvage therapy. Cemiplimab, a fully human antibody to PD-1, was…”
Get full text

Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin by Estévez-García, Purificación, Guerra-Alia, Eva M, de Aranguiz, Blanca Hernando Fernández, González-Martín, Antonio, Rubio, María Jesús, Carbó-Bagué, Anna, Romero, Ignacio, Robles-Barraza, Carlos E, Corbellas, Miguel, Martínez-García, Jerónimo, Gordon, María del Mar, González-Haba, Alba, de Prado, Diego Soto, de Sande, Luis Miguel, Manzano, Aránzazu

“…Background Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is approved for the treatment of patients with platinum-sensitive relapsed…”
Get full text